Evidence for an effect of ACE inhibitors on cancer cachexia.
作者信息
Schanze Nancy, Springer Jochen
机构信息
Applied Cachexia Research, Department of Cardiology, Charité Medical School, Berlin, Germany.
出版信息
J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):139. doi: 10.1007/s13539-012-0072-8. Epub 2012 May 25.
Abstract
摘要
相似文献
1
Evidence for an effect of ACE inhibitors on cancer cachexia.血管紧张素转换酶抑制剂对癌症恶病质影响的证据。
J Cachexia Sarcopenia Muscle. 2012 Jun;3(2):139. doi: 10.1007/s13539-012-0072-8. Epub 2012 May 25.
2
The Effect of ACE Inhibitor on the Quality of Life amongst Patients with Cancer Cachexia.血管紧张素转换酶抑制剂对癌症恶病质患者生活质量的影响。
Asian Pac J Cancer Prev. 2020 Feb 1;21(2):325-330. doi: 10.31557/APJCP.2020.21.2.325.
3
Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia.抑制肾素-血管紧张素系统可改善轻度或重度癌性恶病质小鼠的生理结局。
Int J Cancer. 2013 Sep 1;133(5):1234-46. doi: 10.1002/ijc.28128. Epub 2013 Mar 16.
4
[Heart failure and cachexia].[心力衰竭与恶病质]
Arch Mal Coeur Vaiss. 2006 Dec;99(12):1203-9.
5
New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss.与低骨骼肌指数和体重减轻定义的癌症恶病质相关的新遗传特征。
J Cachexia Sarcopenia Muscle. 2017 Feb;8(1):122-130. doi: 10.1002/jcsm.12138. Epub 2016 Aug 5.
6
Prognosis and therapy approaches of cardiac cachexia.心脏恶病质的预后与治疗方法
Curr Opin Cardiol. 2006 May;21(3):229-33. doi: 10.1097/01.hco.0000221585.94490.09.
7
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia.用于恶病质潜在多模式治疗的研究性组蛋白去乙酰化酶抑制剂的新进展。
Expert Opin Investig Drugs. 2019 Feb;28(2):179-189. doi: 10.1080/13543784.2019.1557634. Epub 2018 Dec 14.
8
The small intestine: a critical linkage in pathophysiology of cardiac cachexia.小肠：心脏恶病质病理生理学的关键联系。
Int J Cardiol. 2010 Aug 20;143(2):200-1. doi: 10.1016/j.ijcard.2008.11.168. Epub 2009 Jan 26.
9
Angiotensin-converting enzyme inhibitors enhance the effect of cyclooxygenase inhibitors on breast cancer: a nationwide case-control study.血管紧张素转换酶抑制剂增强环氧化酶抑制剂对乳腺癌的作用：一项全国性病例对照研究。
J Hypertens. 2012 Dec;30(12):2432-9. doi: 10.1097/HJH.0b013e328358d42f.
10
Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia.环氧化酶-2抑制剂与抗氧化剂在恶病质治疗中的应用
Curr Opin Support Palliat Care. 2008 Dec;2(4):275-81. doi: 10.1097/spc.0b013e32830f47e4.
引用本文的文献
1
Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice.黑色素瘤诱导的恶病质在小鼠中进行性发展，对各器官系统产生不同影响。
Cell Rep. 2023 Jan 31;42(1):111934. doi: 10.1016/j.celrep.2022.111934. Epub 2022 Dec 29.
2
Therapeutic strategies against cancer cachexia.对抗癌症恶病质的治疗策略。
Eur J Transl Myol. 2019 Feb 27;29(1):7960. doi: 10.4081/ejtm.2019.7960. eCollection 2019 Jan 11.
3
THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES.肾素-血管紧张素系统与骨骼肌生物学：慢性疾病状态下肌肉萎缩的机制
Trans Am Clin Climatol Assoc. 2016;127:245-258.
4
Cardiac cachexia: hic et nunc.心脏恶病质：此时此地。
J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):246-60. doi: 10.1002/jcsm.12118. Epub 2016 Jul 1.
5
Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans?癌症恶病质中导致骨骼肌质量丢失的分子途径——动物模型的研究结果能否应用于人类？
BMC Cancer. 2016 Feb 8;16:75. doi: 10.1186/s12885-016-2121-8.
6
Mechanisms of Cachexia in Chronic Disease States.慢性病状态下恶病质的机制。
Am J Med Sci. 2015 Oct;350(4):250-6. doi: 10.1097/MAJ.0000000000000511.
7
Cachexia and pancreatic cancer: are there treatment options?恶病质与胰腺癌：有治疗选择吗？
World J Gastroenterol. 2014 Jul 28;20(28):9361-73. doi: 10.3748/wjg.v20.i28.9361.
8
Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model.罗格列酮和咪达普利单独使用或联合使用可减轻小鼠癌症恶病质模型中的肌肉和脂肪消耗。
Tumour Biol. 2014 Jan;35(1):323-32. doi: 10.1007/s13277-013-1043-1.
9
Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology.2010 至 2012 年肌肉减少症和恶病质的机制和治疗研究要点及其与心脏病学的相关性。
Arch Med Sci. 2013 Feb 21;9(1):166-71. doi: 10.5114/aoms.2013.33356.
本文引用的文献
1
Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia.生长激素、胰岛素样生长因子1与胰岛素信号传导——身体消瘦和恶病质的一个药理学靶点。
J Cachexia Sarcopenia Muscle. 2011 Dec;2(4):191-200. doi: 10.1007/s13539-011-0043-5. Epub 2011 Oct 20.
2
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.《恶病质、肌肉减少症与肌肉杂志》的作者署名及发表伦理准则
J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):7-8. doi: 10.1007/s13539-010-0003-5. Epub 2010 Oct 26.
3
Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia.血管紧张素II通过泛素-蛋白酶体蛋白水解途径直接诱导肌肉蛋白分解代谢，可能在癌症恶病质中起作用。
Br J Cancer. 2005 Aug 22;93(4):425-34. doi: 10.1038/sj.bjc.6602725.
Zotero 插件